Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Artichoke power: new study tests veggie supplement to stop diabetes

NCT ID NCT07415720

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking a daily supplement made from artichoke by-products, combined with a calorie-controlled Mediterranean diet, can help prevent type 2 diabetes in people who are overweight or obese. Researchers will measure changes in insulin resistance and weight over time. The goal is to find a simple, natural way to reduce diabetes risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI between 25.0 and 35.0 kg/m² * HOMA-IR ≥ 2.5. * Adequate physical examination and vital signs or clinically irrelevant to the intervention (those not related to metabolic health). * Subjects must be able to understand and be willing to sign the informed consent form, and must comply with all study procedures and requirements. * Subjects must have a stable means of communication, either by email and/or telephone. Exclusion Criteria: * Weight loss of more than 5% in the last 6 months prior to surgery. * Consumption of antibiotics in the 3 months prior to the intervention. * Subjects who are undergoing treatment for weight loss/body composition modification, use medication for weight loss or blood glucose control, or have had weight loss surgery. * Have a medical diagnosis of type 1 or type 2 diabetes. * History of inflammatory bowel disease and/or resection of the large or small intestine. Subjects with relevant functional or structural abnormalities of the digestive system. * Inability to follow the recommended diet or physical exercise. * Unavailability in terms of time or location to attend study visits. * Failure to sign the informed consent form. * Inability to communicate with the research team. * Endocrine-related excess weight (except for treated hypothyroidism, at least 3 months of stable treatment). * Being pregnant or planning a pregnancy during the intervention period. * Being breastfeeding. * Having an allergy to artichokes. * Severe psychiatric illnesses that have required hospitalisation in the last 6 months. * Renal failure. * Having immunodeficiency or being HIV positive. * Being treated with immunosuppressive drugs or cytotoxic agents. * High alcohol intake: more than 14 units (women) and 20 units (men) per week. * Participation in another randomised clinical trial. * Volunteers undergoing drug treatment for less than 3 months with a stable dose/stable treatment. * Taking nutritional supplements (supplements: plant derivatives, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for 3 months prior to the start of the trial. * Taking nutritional supplements (supplements: plant-derived, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for the 16 weeks of the study intervention and a minimum washout period of 14 days prior to baseline measurements is guaranteed. * Having donated blood in the 14 days prior to the baseline visit. * Subjects with any type of cancer or undergoing treatment for cancer, or who have not been in remission for at least 5 years. * Any other condition that may interfere with adherence to the intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.